EUROSTAM

A Europe-wide Strategy to enhance Transplantation of highly sensitized patients on basis of Acceptable HLA Mismatches

Coordinatore	ACADEMISCH ZIEKENHUIS LEIDEN    more  Organization address address: Albinusdreef 2 city: LEIDEN postcode: 2333 ZA contact info Titolo: Prof. Nome: Frans Cognome: Claas Email: send email Telefono: 31715263802
Nazionalità Coordinatore	Netherlands [NL]
Totale costo	3˙737˙167 €
EC contributo	2˙623˙500 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2012-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-12-01   -   2015-11-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	ACADEMISCH ZIEKENHUIS LEIDEN  Organization address address: Albinusdreef 2 city: LEIDEN postcode: 2333 ZA contact info Titolo: Prof. Nome: Frans Cognome: Claas Email: send email Telefono: 31715263802	NL (LEIDEN)	coordinator	777˙900.00
2	MULTIPLICOM NV  Organization address address: GALILEILAAN 18 city: NIEL postcode: 2845 contact info Titolo: Mr. Nome: Luc Cognome: Lammens Email: send email Telefono: 32499525452	BE (NIEL)	participant	474˙400.00
3	NHS BLOOD AND TRANSPLANT  Organization address address: OAK HOUSE REEDS CRESCENT city: WATFORD postcode: WD24 4QN contact info Titolo: Dr. Nome: Susan Cognome: Fuggle Email: send email Telefono: 1865226162	UK (WATFORD)	participant	303˙500.00
4	CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER  Organization address address: CALLE ROSSELLO 149 PUERTA BJS city: BARCELONA postcode: 8036 contact info Titolo: Ms. Nome: Elen Cognome: Garcia Email: send email Telefono: +34 93 227 92 04 Fax: +34 93 227 92 05	ES (BARCELONA)	participant	278˙000.00
5	Nome Ente NON disponibile  Organization address address: Videnska 1958/9 city: PRAGUE 4 postcode: 14021 contact info Titolo: Dr. Nome: Antonij Cognome: Slavcev Email: send email Telefono: 420236000000	CZ (PRAGUE 4)	participant	213˙200.00
6	ABSORBER AB  Organization address address: FRANZENGATAN 5 city: STOCKHOLM postcode: 102 27 contact info Titolo: Dr. Nome: Hakan Cognome: Hall Email: send email Telefono: 46766276550	SE (STOCKHOLM)	participant	210˙500.00
7	ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST  Organization address address: PRESCOT STREET city: LIVERPOOL postcode: L7 8XP contact info Nome: Nn Cognome: Nn Email: send email Telefono: +44 1517064246	UK (LIVERPOOL)	participant	137˙000.00
8	UNIVERSITE DE GENEVE  Organization address address: Rue du General Dufour 24 city: GENEVE postcode: 1211 contact info Titolo: Prof. Nome: Alicia Cognome: Sanchez-Mazas Email: send email Telefono: 41223796984 Fax: 41223793194	CH (GENEVE)	participant	137˙000.00
9	STICHTING EUROTRANSPLANT INTERNATIONAL FOUNDATION  Organization address address: PLESMANLAAN 100 city: LEIDEN postcode: 2332 CB contact info Titolo: Dr. Nome: Arie Cognome: Oosterlee Email: send email Telefono: 31715795795	NL (LEIDEN)	participant	92˙000.00
10	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS  Organization address address: 3 Avenue Victoria city: PARIS postcode: 75004 contact info Titolo: Dr. Nome: Denis Cognome: Glotz Email: send email Telefono: 33142499631	FR (PARIS)	participant	0.00
11	GENERAL HOSPITAL OF ATHENS G.GENNIMATAS GGHA  Organization address address: MESOGEION AVENUE 154 city: ATHINA postcode: 115 27 contact info Titolo: Dr. Nome: Aliki Cognome: Iniotaki Email: send email Telefono: 302108000000	EL (ATHINA)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The presence of donor specific HLA antibodies is a contra-indication for renal transplantation. Highly sensitized patients accumulate and often die on the transplant waiting lists as it is almost impossible to find donors towards which they don’t have antibodies. The acceptable mismatch program of Eurotransplant has shown to be an effective tool to enhance successful transplantation of highly sensitized patients. However, 35% of the patients have rare HLA phenotypes and no suitable donor can be found. HLA phenotype frequencies vary amongst European populations. Rare HLA phenotypes in one population are more frequent in other populations. The major objective of the 10 partners in this project is to analyze the feasibility and requirements for a Europe-wide acceptable mismatch program to enhance transplantation of patients with rare HLA phenotypes in their own population. Long waiting patients will be matched with virtual donors based on known HLA frequencies of different European populations and with actual donors from the different transplant organizations. If successful, the logistics will be tested by transplanting some of these patients with donors from elsewhere in Europe. Second objective is to simplify the definition of acceptable HLA mismatches. Although almost 4000 HLA class I antigens are known, only 150 polymorphic residues differentially spread over the different HLA antigens are responsible for the induction of antibodies. An innovative typing and matching strategy based on the definition of acceptable HLA epitopes will facilitate the identification of suitable donors. Third objective is to define whether antibodies against non-HLA targets on the donor endothelium affect the results of transplants in highly sensitized patients. The aims of this collaborative project are fully compatible with those required for the program Health.2012.1.4-1. In objectives 2 and 3 two partners belonging to the SME sector of the European industry are involved.'

Introduzione (Teaser)

The success of organ transplantation is highly dependent on matching the donor organ with the recipient. A pan-European innovative typing and matching should enhance the identification of suitable donors.